Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07435662 · ClinicalTrials.gov registry record · NA

Optimizing Heart Failure Therapies Among Patients With Limited Access in Denver

A NA study of Heart Failure and Medication Optimization, sponsored by Denver Health and Hospital Authority.

Recruiting
Registry status
NA
Development phase
40
Enrollment target
1
Study location

NCT07435662: Recruiting NA study of Heart Failure and Medication Optimization, sponsored by Denver Health and Hospital Authority.

NCT07435662 is a NA study of Heart Failure and Medication Optimization that is actively recruiting participants, run by Denver Health and Hospital Authority. The registered enrollment target is 40 participants, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07435662, a NA study of Heart Failure and Medication Optimization, is actively recruiting participants, sponsored by Denver Health and Hospital Authority.

RECRUITING
Registry status
NA
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

Numerous pharmacotherapies have been proven to reduce mortality and hospitalization rates for heart failure with reduced ejection fraction (HFrEF) patients. However, these are underutilized clinically, preventing realization of proven benefits. Simplified patient education tools and multidisciplinary teams including pharmacists have been used to improve medication optimization but in predominantly private payer groups. This study will translate these evidence-based interventions to patients with limited access to care. In this randomized, prospective study, patients with HFrEF at a local hospital dedicated to care for participants with limited access will receive either pharmacist-directed medication adjustment visits with patient education materials or standard of care. This study will assess the hypothesis that the implementation of the intervention is feasible in this population, as demonstrated by the number of visits and proportion of visits with medication adjustments. Further, medication dosing in each arm will be evaluated via the Kansas City Medication Optimization (KCMO) score, which will average the percentage of maximal doses of appropriate HFrEF medication classes a patient is on. The change in KCMO scores over the course of the pilot in the two arms will then be compared to assess the hypothesis that the intervention will better increase patients' KCMO scores than the standard of care. The findings of this study will help address knowledge gaps in the care of patients not well represented previously in the literature. This proposal addresses the translational science roadblock of recruitment and engagement of participants with limited access to care.

Interventions

  • OTHER Pharmacy follow up

Study Locations (1)

Colorado

  • Denver Health and Hospital Authority - Denver

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2025-10-01
Est. Completion 2026-07-01
Phase NA

What NCT07435662 shows while recruiting

NCT07435662 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (98% lower).

The record links to 2 conditions, with Heart Failure appearing as the primary indexed condition, and to 1 intervention - of which Pharmacy follow up is the first listed.

NCT07435662 reports a single indexed study location in Colorado.

Frequently Asked Questions

What is clinical trial NCT07435662 about?

NCT07435662 is a clinical study titled "Optimizing Heart Failure Therapies Among Patients With Limited Access in Denver". Numerous pharmacotherapies have been proven to reduce mortality and hospitalization rates for heart failure with reduced ejection fraction (HFrEF) patients. However, these are underutilized clinically, preventing realization of proven benefits. Simplified patient education tools and multidisciplinar...

What is the current status of trial NCT07435662?

This trial is currently recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2025-10-01. Estimated completion is 2026-07-01.

What conditions does trial NCT07435662 study?

This clinical trial studies the following conditions: Heart Failure, Medication Optimization.

What interventions are being tested in trial NCT07435662?

The interventions under investigation include: Pharmacy follow up (OTHER).

Who is sponsoring clinical trial NCT07435662?

This trial is sponsored by Denver Health and Hospital Authority, which has 73 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07435662 being conducted?

This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Heart Failure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07435662's enrollment target sits among peer trials

40 306th of 397 higher than 89 of 397 other Heart Failure trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07435662, the US trial registry maintained by the National Library of Medicine. NCT07435662 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.